Small-aperture corneal inlay for the correction of presbyopia: 3-year follow-up

Abstract

These 3-year results support the safety and efficacy of the corneal inlay to correct presbyopia in naturally emmetropic presbyopic patients. However, despite a significant gain in UNVA and UIVA, 28.3% of patients lost 1 line of CDVA.

Comparison of binocular through-focus visual acuity with monovision and a small aperture inlay

“…The efficacy of small aperture monovision [4,5,21,22,26] and traditional monovision [20,[27][28][29] has been investigated in several studies. However, no direct comparison has been performed so far.…”

“…Based on small-aperture monovision, it extends depth of focus (DOF) of the eye it is implanted in [3]. Clinical studies support efficacy and safety of the device for presbyopia treatment with published data of up to three years [4][5][6]. The intrastromal corneal inlay is a 5 μm thick polyvinylidene fluoride ring opacified by carbon nanoparticles.…”

Reading performance and patient satisfaction after corneal inlay implantation for presbyopia correction: Two-year follow-up

“…The development of materials with enhanced biocompatibility, 7,8 advances in technology such as femtosecond lasers, and a better understanding of physiology and the wound-healing response have allowed corneal inlay technology to mature. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] Currently available presbyopia-correcting corneal inlays are based on creating a hyperprolate cornea by inserting a space-occupying inlay (VueC, Revision Optics, Inc.), 13 generating a bifocal optic by implanting refractive annular addition lenticules (Flexivue Q 2012 ASCRS and ESCRS 0886-3350/$ -see front matterPublished by Elsevier Inc. http://dx. …”

“…[10][11][12][13][14][15][16][17] Since approval by the authorities of the Conformit ee Europ eenne (CE-mark) in 2005, refractive surgeons have been able to implant the Kamra corneal inlay outside clinical trials on a commercial basis, whereas the technique is still under investigation in U.S. Food and Drug Administration (FDA) clinical trials for the treatment of near-plano and plano presbyopia. [10][11][12][13][14][15][16][17] Designed to increase the depth of focus based on the principle of small-aperture optics, the corneal inlay was designed to improve uncorrected near and intermediate vision while minimally affecting distance vision. 10 Mid-term and long-term studies support the efficacy and safety of this inlay for the treatment of presbyopia, with published data for up to 4 years.…”

“…10 Mid-term and long-term studies support the efficacy and safety of this inlay for the treatment of presbyopia, with published data for up to 4 years. [10][11][12][14][15][16][17] The main intention of the Kamra corneal inlay is to improve uncorrected near vision; thus, the assessment of reading performance is considered to be the most important clinical examination for evaluating the benefits of this presbyopia treatment. 12,14 The Salzburg Reading Desk measures reading performance using computerized testing under standardized conditions while simulating a natural reading process.…”